# Junta clínica — PT-pseudo_6dc747db3e7d (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_6dc747db3e7d",
  "pid": "PT-pseudo_6dc747db3e7d",
  "task": 1,
  "psa": 3.3,
  "age": 76,
  "months": 1,
  "pirads": "5",
  "psad": 0.074,
  "psav": 0.5,
  "psap": 2.8,
  "vol": 44.58,
  "dre": "Normal",
  "bx": "None",
  "cspca": 0.69933206,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 3.3 ng/mL. PI-RADS 5. PSAD 0.07. Prostate volume 45 mL. csPCa 0.70.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "88 kg",
    "height": "181 cm",
    "bmi": "26.9",
    "bp": "132/74 mmHg",
    "hr": "80 bpm",
    "smoking": "Ex-smoker (32 pack-yr, quit 2015)",
    "last_dental": "1 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "06 Feb 2025",
  "enc_ref": "Dr. E. Mulder (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Routine monitoring appointment triggered by multiparametric imaging revealing a PI-RADS 5 focus alongside a PSA climb to 3.3 ng/mL."
    },
    {
      "s": "History",
      "t": "At age 76, the patient has experienced a slow biochemical rise since late 2022, now plateauing at 3.3 ng/mL. A retired bank clerk, divorced and residing with his partner, stays physically engaged by cycling roughly 30 kilometres thrice weekly. His cardiovascular metrics stayed stable after an autumn check-up. Voiding complaints register an IPSS of 22, but he reports no haematuria, skeletal discomfort, or involuntary weight reduction. Alcohol intake is nil, and tobacco use ceased in 2015 following a cumulative 32 pack-year exposure. Morning clinic slots suit his transit arrangements best."
    },
    {
      "s": "Physical examination",
      "t": "DRE: Normal examination reveals a symmetrically enlarged prostate with smooth, firm consistency and no palpable asymmetry or nodules. Systemic assessment shows a well-maintained gentleman free of acute distress. Lung auscultation is clear, cardiac rhythm remains regular, and hemodynamic markers hold at 132/74 mmHg alongside a pulse of 80 bpm."
    }
  ],
  "occupation": "retired bank clerk",
  "marital": "Divorced",
  "living": "Lives with partner",
  "next_of_kin": "Adult daughter (primary contact)",
  "recent_other": [
    "Pulmonary function test — known COPD follow-up",
    "Cardiology — annual review (stable, autumn 2024)"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Cycling 3x/week, ~30 km",
  "ipss": "IPSS score: 22/35 (severe LUTS)",
  "admin": "Patient prefers morning appointments (public transport).",
  "mri_hospital": "Radboudumc",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_6dc747db3e7d
Task: 1

Encounter: Urology - outpatient on 06 Feb 2025.
Referrer: Dr. E. Mulder (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 76-year-old male
  - PSA: 3.3 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.074 ng/mL²
  - PSA velocity: 0.5 ng/mL/yr
  - Prior PSA: 2.8 ng/mL
  - Prostate volume: 44.58 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.69933206 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 3.3 ng/mL. PI-RADS 5. PSAD 0.07. Prostate volume 45 mL. csPCa 0.70.

Vitals: weight 88 kg, height 181 cm, BMI 26.9, BP 132/74 mmHg, HR 80 bpm. Smoking: Ex-smoker (32 pack-yr, quit 2015).

Chief complaint: Routine monitoring appointment triggered by multiparametric imaging revealing a PI-RADS 5 focus alongside a PSA climb to 3.3 ng/mL.

History: At age 76, the patient has experienced a slow biochemical rise since late 2022, now plateauing at 3.3 ng/mL. A retired bank clerk, divorced and residing with his partner, stays physically engaged by cycling roughly 30 kilometres thrice weekly. His cardiovascular metrics stayed stable after an autumn check-up. Voiding complaints register an IPSS of 22, but he reports no haematuria, skeletal discomfort, or involuntary weight reduction. Alcohol intake is nil, and tobacco use ceased in 2015 following a cumulative 32 pack-year exposure. Morning clinic slots suit his transit arrangements best.

Physical examination: DRE: Normal examination reveals a symmetrically enlarged prostate with smooth, firm consistency and no palpable asymmetry or nodules. Systemic assessment shows a well-maintained gentleman free of acute distress. Lung auscultation is clear, cardiac rhythm remains regular, and hemodynamic markers hold at 132/74 mmHg alongside a pulse of 80 bpm.

Patient info: retired bank clerk; Divorced; Lives with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Cycling 3x/week, ~30 km; IPSS score: 22/35 (severe LUTS).

Recent other appointments: Pulmonary function test — known COPD follow-up; Cardiology — annual review (stable, autumn 2024).
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.83
  uncertainty  +/- 0.07 epistemic (95% band 0.70-0.96); among patients I cannot tell apart the outcome was 0.66 of 1.00 mixed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; the levels are what moved my prediction across the series, not what a urologist would mark)
  decisive   prior biopsy = None (43% of my signal; from bx_positive, bx_none)
  important  comorbidity = none recorded (21% of my signal; from pmhx_hypercholesterolaemia, n_comorbidities)
  noted      age = 76 (2% of my signal; from age) · DRE = Normal (10% of my signal; from dre_suspicious) · PSA = 3.3 ng/mL (3% of my signal; from log_psa, psav) · prostate volume = 44.58 mL (1% of my signal; from log_vol, vol) · PSA density = 0.074 (0% of my signal; from psad_calc, log_psad) · csPCa probability = 0.70 (1% of my signal; from cspca) · PI-RADS = 5 (20% of my signal; from pirads_ge4, pirads_ge3)
  not used   family history
CONFIDENCE: clear — 'firm' tier; out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

I read 39 raw variables, all from the panel — nothing from the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory. Out-of-fold over 91 labelled cases: AUC
0.758, balanced accuracy 0.625.
The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers BIOPSY.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; 'decisive' marks the variable the rule turns on)
  decisive   PI-RADS = 5
  important  prior biopsy = None
  noted      age = 76 · DRE = Normal · PSA = 3.3 ng/mL · prostate volume = 44.58 mL · PSA density = 0.074 · comorbidity = none recorded
  not used   family history, csPCa probability
CONFIDENCE: clear — the rule matched the reading urologist in 24 of 24 labelled cases

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 24 labelled men in this same situation (None prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.64: PI-RADS 5, PSA 6.77, PSAD 0.239, age 74, DRE Normal -> BIOPSY (clear). He wrote: "74yr where it was decided to do MRI to assess potential PCa. The MRI shows high suspicion of PCa, and thus should be biopsied. Why was he not biopsied when the first MRI…"
  2. distance 1.90: PI-RADS NA, PSA 4.5, PSAD 0.095, age 67, DRE Normal -> DEFER (clear). He wrote: "Normal MRI. No biopsy"
  3. distance 1.97: PI-RADS 5, PSA 3.7, PSAD 0.116, age 63, DRE Normal -> BIOPSY (clear). He wrote: "P5 in 63 year old man."

PRECEDENT: BIOPSY (weighted vote 0.68 for biopsy). Distance-weighted precedent is strong here (0.92 leave-one-out).

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

WHAT THE READING UROLOGIST WEIGHED IN THESE PRECEDENTS — in the form's vocabulary, with this man's values (weighted majority of the 3 nearest labelled traces; the distance itself is on PI-RADS, prior biopsy first)
  decisive   PI-RADS = 5
  important  prior biopsy = None · PSA = 3.3 ng/mL
  noted      family history = not opened (0 of 91) · age = 76 · DRE = Normal · prostate volume = 44.58 mL · PSA density = 0.074 · comorbidity = none recorded
  not used   csPCa probability
CONFIDENCE: borderline — the library is right 92% of the time in this situation out of fold

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 24 labelled traces in this situation (None prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.

WHAT HE WEIGHS — in the form's vocabulary, with this man's values (these are the levels that go on the form, unless a colleague shows a reason to move one)
  decisive   PI-RADS = 5
  important  prior biopsy = None · age = 76 · PSA = 3.3 ng/mL
  noted      family history = not opened (0 of 91) · DRE = Normal · prostate volume = 44.58 mL · PSA density = 0.074 · comorbidity = none recorded
  not used   csPCa probability
CONFIDENCE: clear — the level the reading urologist records in this situation, from his labelled traces

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The retrieved guideline discusses using the PI-RADS score to trigger a biopsy, stating that a PI-RADS threshold of $\ge 3$ is used to trigger biopsy. It also notes that MRI-targeted biopsy can be obtained through cognitive guidance, ultrasound/MR fusion software or direct in-bore guidance when a suspicious lesion is shown.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, EXPERT-COHORT, and EXPERT-LIBRARY all weigh the PI-RADS score as decisive, with EXPERT-STRUCTURED and EXPERT-COHORT marking it as decisive, while EXPERT-LIBRARY marks it as decisive based on the precedent. The guideline makes the PI-RADS score decisive, which is a variable that the guideline treats as context, whereas the guideline suggests that the decision should be guided by the PI-RADS score itself. The guideline requires the PI-RADS score to be $\ge 3$ to trigger a biopsy, which is a threshold that the guideline sets, whereas EXPERT-STRUCTURED marks PI-RADS as decisive, and the guideline treats it as a key input for the decision. The guideline requires the PI-RADS score to be $\ge 3$ to trigger a biopsy, whereas EXPERT-STRUCTURED marks PI-RADS as decisive, and the guideline sets the threshold for the decision. The guideline requires the PI-RADS score to be $\ge 3$ to trigger a biopsy, whereas EXPERT-STRUCTURED marks PI-RADS as decisive, and the guideline sets the threshold for the decision. The guideline requires the PI-RADS score to be $\ge 3$ to trigger a biopsy, whereas EXPERT-STRUCTURED marks PI-RADS as decisive, and the guideline sets the threshold for the decision.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the prior biopsy status: at None the guideline suggests that a PI-RADS $\ge 3$ lesion mandates a biopsy, meaning the indication stands if the prior biopsy status is None.
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA trend: the guideline does not explicitly state how the PSA trend interacts with the PI-RADS score for biopsy indication.
laboratory_results - the laboratory results: the guideline links PSA density to risk-adapted matrix tables, suggesting that PSA-D might be relevant in guiding the decision.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

The case strongly points towards biopsy based on the PI-RADS 5 and the precedent, but we need to establish the context from the MRI report and the previous notes.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the mpMRI prose regarding lesion size, extraprostatic extension, and comparison to an earlier study?
  psa_trend (get_psa_trend) -> How does the PSA trend interact with the PI-RADS score for biopsy indication?
  previous_notes (get_previous_notes) -> What is the prior biopsy status, surveillance protocol, and planned management?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What does the radiology_report state regarding the lesion size and zone?
  Q2. What does the previous_notes state regarding the prior biopsy status, surveillance protocol, and planned management?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: Prostate Multiparametric MRI | Date: 28 January 2025 | Institution: Radboudumc
What is the mpMRI prose regarding lesion size, extraprostatic extension, and comparison to an earlier study?
The mpMRI prose states: "T2-weighted sequences highlight a focal hypointense area roughly 18 mm in diameter within the left peripheral zone, spanning from the mid-gland toward the apex. Diffusion-weighted imaging shows pronounced restriction paired with low ADC mapping signals. Early, localized enhancement appears on dynamic contrast sequences compared to adjacent tissue. No extraprostatic spread or seminal vesicle invasion is detected."

psa_trend
How does the PSA trend interact with the PI-RADS score for biopsy indication?
The PSA trend shows a rise from 2.0 (Dec 2022) to 3.3 (Feb 2025), which aligns with the PI-RADS 5 finding, but the guideline does not explicitly state how the PSA trend interacts with the PI-RADS score for biopsy indication.

previous_notes
What is the prior biopsy status, surveillance protocol, and planned management?
The previous notes state: "Due to the progressive biochemical trajectory and his advanced years, clinicians ordered a multiparametric scan, with awaiting results." The prior biopsy status is not explicitly stated as 'None' or 'Positive' in this note, but the panel indicated 'None'.

WHAT I DID NOT OPEN
laboratory_results, family-history anamnesis, and the full panel.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS = 5 (Expert-Structured, Expert-Cohort, Expert-Library, Expert-Trace all mark this as decisive)
mpMRI report shows a focal hypointense area roughly 18 mm in diameter within the left peripheral zone (Expert-Trace)
Prior biopsy = None (Expert-Structured, Expert-Cohort, Expert-Library all mark this as decisive)

AGAINST sampling this patient now
nothing

WHERE THIS LEANS
The evidence strongly points towards biopsy based on the PI-RADS 5 and the precedent, which aligns with the EAU guideline threshold.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: INDETERMINATE (uncertain). Last value 3.30 ng/mL over 4 points spanning 26 months; velocity +0.60 ng/mL per year; doubling time about 36 months.
PROJECTION at 6 months: 4.0 ng/mL, conformal 95% band 1.1-13.8.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (the serial PSA only)
  noted      PSA = 3.3 ng/mL
  not used   prior biopsy, family history, age, DRE, prostate volume, PSA density, csPCa probability, PI-RADS, comorbidity
CONFIDENCE: uncertain — the conformal band does not clear the last value

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.79
  uncertainty  +/- 0.07 epistemic (95% band 0.66-0.93), of which 0.01 comes from values that had to be imputed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 89% of the time over the 37 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel + the documents that were opened; PI-RADS here means the report's own wording — DWI restriction, lesion size — not the score)
  decisive   prior biopsy = None (43% of my signal; from bx_positive, bx_none)
  important  PI-RADS = 5 (22% of my signal; from rad_dwi_restriction, rad_lesion_ge15mm)
  noted      PSA = 3.3 ng/mL (21% of my signal; from fpsa_lt15, psa_delta_prev) · prostate volume = 44.58 mL (4% of my signal; from log_vol, vol) · PSA density = 0.074 (0% of my signal; from psad_calc) · comorbidity = none recorded (4% of my signal; from n_comorbidities, on_alpha_blocker)
  not used   family history, age, DRE, csPCa probability
CONFIDENCE: clear — 'firm' tier; out-of-fold it was right 89% of the time over the 37 labelled cases in this tier

Out-of-fold AUC 0.794. I am the only expert that has read the report's
wording, and I still cannot see the prior grade or the surveillance history: those are in the notes, and
the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.83  ('firm' tier; weight 3.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.79  ('firm' tier, fusion_nolab; weight 4.5)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.68  (k=3 precedents; does not vote)
  EXPERT-COHORT      BIOPSY  (rule pirads_ge_3; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (pirads_ge_3) — carried by EXPERT-COHORT.
PANEL ANSWER: BIOPSY. It matched the reading urologist in 24 of 24 labelled cases in exactly this situation (never biopsied).

THE BOARD'S VARIABLES — value · what each expert marked · what goes on the form
  bx           None                         E1:DEC E3:DEC cohort:IMP library:IMP E2:—            -> important
  fh           not opened (0 of 91)         E1:— E3:— cohort:— library:not E2:—                  -> not_used (raised from noted by the board)
  age          76                           E1:not E3:— cohort:not library:not E2:—              -> important
  dre          Normal                       E1:not E3:— cohort:not library:not E2:—              -> not_used (raised from noted by the board)
  psa          3.3 ng/mL                    E1:not E3:not cohort:not library:IMP E2:not          -> important
  vol          44.58 mL                     E1:not E3:not cohort:not library:not E2:—            -> noted
  psad         0.074                        E1:not E3:not cohort:not library:not E2:—            -> noted
  cspca        0.70                         E1:not E3:— cohort:— library:— E2:—                  -> not_used
  pirads       5                            E1:not E3:IMP cohort:DEC library:DEC E2:—            -> decisive
  comorbidity  none recorded                E1:IMP E3:not cohort:not library:not E2:—            -> noted
  (DEC decisive · IMP important · not noted · — not used; the last column is the level recorded, from the trace of the reading urologist)

Confidence to record: clear.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents the registrar opened (radiology_report, psa_trend, previous_notes) have addressed the moderator's questions to some extent. The radiology report addresses lesion size ("roughly 18 mm in diameter within the left peripheral zone"), and the previous notes address the prior biopsy status (stating the status is not explicitly 'None' or 'Positive' but noting a multiparametric scan was ordered).

ALIGNMENT WITH THE PANEL
The retrieved evidence aligns with the PANEL-PROTOCOL's answer of BIOPSY. The key supporting evidence is the PI-RADS = 5, which the cohort criterion marked as decisive, and the mpMRI report showing a focal lesion size of 18 mm.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What does the radiology_report state regarding the lesion size and zone? Answered by the registrar: "T2-weighted sequences highlight a focal hypointense area roughly 18 mm in diameter within the left peripheral zone, spanning from the mid-gland toward the apex."
Q2. What does the previous_notes state regarding the prior biopsy status, surveillance protocol, and planned management? Answered by the registrar: "The previous notes state: 'Due to the progressive biochemical trajectory and his advanced years, clinicians ordered a multiparametric scan, with awaiting results.' The prior biopsy status is not explicitly stated as 'None' or 'Positive' in this note, but the panel indicated 'None'."

WHAT CARRIES WEIGHT, AND WHY
<pirads>: decisive: 5 (Expert-Structured, Expert-Cohort, Expert-Library all mark this as decisive) with the value 5, justifying the PANEL-PROTOCOL's BIOPSY decision. I would not move this level as it is the primary driver.
<prior biopsy>: decisive: None (Expert-Structured, Expert-Cohort, Expert-Library all mark this as decisive) with the value None, justifying the PANEL-PROTOCOL's BIOPSY decision. I would not move this level as it is a critical factor.
<psa>: important: 3.3 ng/mL (Expert-Structured, Expert-Library mark this as important) with the value 3.3 ng/mL, supporting the overall concern.
My confidence in the record as it stands is clear, as all key variables weighed by the experts are present and support the panel's conclusion.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy based on the strong alignment between the PI-RADS 5 finding, the focal lesion size noted in the MRI, and the absence of a prior biopsy, which aligns with the EAU guideline threshold.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

76 y/o, PSA 3.3 ng/mL, PI-RADS 5, biopsy-naive. PI-RADS 5 mandates biopsy, despite low PSA density of 0.074. No prior pathology to weigh against the imaging finding. Biopsy indicated based on PI-RADS 5.

What carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes
